메뉴 건너뛰기




Volumn 112, Issue 2, 2015, Pages 217-226

Beyond BRAF: Where next for melanoma therapy?

Author keywords

Beyond BRAF; Melanoma; Targeted therapy

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN;

EID: 84921916400     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.476     Document Type: Short Survey
Times cited : (98)

References (95)
  • 2
    • 0021258276 scopus 로고
    • Transforming ras genes from human melanoma: A manifestation of tumour heterogeneity?
    • Albino AP, Le Strange R, Oliff AI, Furth ME, Old LJ (1984) Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature 308(5954): 69-72.
    • (1984) Nature , vol.308 , Issue.5954 , pp. 69-72
    • Albino, A.P.1    Le Strange, R.2    Oliff, A.I.3    Furth, M.E.4    Old, L.J.5
  • 5
    • 84902668772 scopus 로고    scopus 로고
    • MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma
    • Asundi J, Lacap JA, Clark S, Nannini M, Roth L, Polakis P (2014) MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma. Mol Cancer Ther 13(6): 1599-1610.
    • (2014) Mol Cancer Ther , vol.13 , Issue.6 , pp. 1599-1610
    • Asundi, J.1    Lacap, J.A.2    Clark, S.3    Nannini, M.4    Roth, L.5    Polakis, P.6
  • 7
    • 84893732985 scopus 로고    scopus 로고
    • Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib
    • Azer MWF, Menzies AM, Haydu LE, Kefford RF, Long GV (2014) Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib. Cancer 120(4): 530-536.
    • (2014) Cancer , vol.120 , Issue.4 , pp. 530-536
    • Azer, M.W.F.1    Menzies, A.M.2    Haydu, L.E.3    Kefford, R.F.4    Long, G.V.5
  • 8
    • 33846230965 scopus 로고    scopus 로고
    • Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model
    • Bedogni B, Welford SM, Kwan AC, Ranger-Moore J, Saboda K, Powell MB (2006) Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther 5(12): 3071-3077.
    • (2006) Mol Cancer Ther , vol.5 , Issue.12 , pp. 3071-3077
    • Bedogni, B.1    Welford, S.M.2    Kwan, A.C.3    Ranger-Moore, J.4    Saboda, K.5    Powell, M.B.6
  • 15
    • 45449092590 scopus 로고    scopus 로고
    • SnapShot: Ras signaling
    • 1292
    • Cully M, Downward J (2008) SnapShot: Ras signaling. Cell 133 (7): 1292-1292 e1.
    • (2008) Cell , vol.133 , Issue.7
    • Cully, M.1    Downward, J.2
  • 16
    • 28244444919 scopus 로고    scopus 로고
    • Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin
    • da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R (2005) Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65(23): 10686-10691.
    • (2005) Cancer Res , vol.65 , Issue.23 , pp. 10686-10691
    • Da Rocha Dias, S.1    Friedlos, F.2    Light, Y.3    Springer, C.4    Workman, P.5    Marais, R.6
  • 21
    • 65649090993 scopus 로고    scopus 로고
    • BRAF signaling and targeted therapies in melanoma
    • Dhomen N, Marais R (2009) BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23(3): 529-545ix.
    • (2009) Hematol Oncol Clin North Am , vol.23 , Issue.3 , pp. 529-545ix
    • Dhomen, N.1    Marais, R.2
  • 22
    • 0037264633 scopus 로고    scopus 로고
    • Targeting RAS signalling pathways in cancer therapy
    • Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3(1): 11-22.
    • (2003) Nat Rev Cancer , vol.3 , Issue.1 , pp. 11-22
    • Downward, J.1
  • 23
    • 33750284658 scopus 로고    scopus 로고
    • In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
    • Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, Bastian BC, Springer C, Marais R (2006) In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 66(19): 9483-9491.
    • (2006) Cancer Res , vol.66 , Issue.19 , pp. 9483-9491
    • Dumaz, N.1    Hayward, R.2    Martin, J.3    Ogilvie, L.4    Hedley, D.5    Curtin, J.A.6    Bastian, B.C.7    Springer, C.8    Marais, R.9
  • 28
    • 58149399847 scopus 로고    scopus 로고
    • Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro
    • Eskandarpour M, Huang F, Reeves KA, Clark E, Hansson J (2009) Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro. Int J Cancer 124(1): 16-26.
    • (2009) Int J Cancer , vol.124 , Issue.1 , pp. 16-26
    • Eskandarpour, M.1    Huang, F.2    Reeves, K.A.3    Clark, E.4    Hansson, J.5
  • 29
    • 84910081356 scopus 로고    scopus 로고
    • Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma
    • e-pub ahead of print 19 June 2014
    • Fedorenko IV, Fang B, Koomen JM, Gibney GT, Smalley KS (2014) Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res; e-pub ahead of print 19 June 2014.
    • (2014) Melanoma Res
    • Fedorenko, I.V.1    Fang, B.2    Koomen, J.M.3    Gibney, G.T.4    Smalley, K.S.5
  • 32
    • 78449275389 scopus 로고    scopus 로고
    • Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells
    • Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70(21): 8736-8747.
    • (2010) Cancer Res , vol.70 , Issue.21 , pp. 8736-8747
    • Gopal, Y.N.1    Deng, W.2    Woodman, S.E.3    Komurov, K.4    Ram, P.5    Smith, P.D.6    Davies, M.A.7
  • 33
    • 30444441778 scopus 로고    scopus 로고
    • V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
    • Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N (2006) V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci US A 103(1): 57-62.
    • (2006) Proc Natl Acad Sci US A , vol.103 , Issue.1 , pp. 57-62
    • Grbovic, O.M.1    Basso, A.D.2    Sawai, A.3    Ye, Q.4    Friedlander, P.5    Solit, D.6    Rosen, N.7
  • 35
    • 84879311843 scopus 로고    scopus 로고
    • Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma
    • Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM, Smalley KS (2013) Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther 12(6): 901-912.
    • (2013) Mol Cancer Ther , vol.12 , Issue.6 , pp. 901-912
    • Haarberg, H.E.1    Paraiso, K.H.2    Wood, E.3    Rebecca, V.W.4    Sondak, V.K.5    Koomen, J.M.6    Smalley, K.S.7
  • 36
  • 37
    • 84900426582 scopus 로고    scopus 로고
    • Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma
    • Hartsough EJ, Basile KJ, Aplin AE (2014) Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res 12(5): 795-802.
    • (2014) Mol Cancer Res , vol.12 , Issue.5 , pp. 795-802
    • Hartsough, E.J.1    Basile, K.J.2    Aplin, A.E.3
  • 40
    • 84903159476 scopus 로고    scopus 로고
    • Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
    • Holderfield M, Deuker MM, McCormick F, McMahon M (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14(7): 455-467.
    • (2014) Nat Rev Cancer , vol.14 , Issue.7 , pp. 455-467
    • Holderfield, M.1    Deuker, M.M.2    McCormick, F.3    McMahon, M.4
  • 45
    • 34347369084 scopus 로고    scopus 로고
    • Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
    • Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG (2007) Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6(7): 541-555.
    • (2007) Nat Rev Drug Discov , vol.6 , Issue.7 , pp. 541-555
    • Konstantinopoulos, P.A.1    Karamouzis, M.V.2    Papavassiliou, A.G.3
  • 53
    • 0037805547 scopus 로고    scopus 로고
    • RAS oncogenes: The first 30 years
    • Malumbres M, Barbacid M (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3(6): 459-465.
    • (2003) Nat Rev Cancer , vol.3 , Issue.6 , pp. 459-465
    • Malumbres, M.1    Barbacid, M.2
  • 55
  • 56
    • 84890062777 scopus 로고    scopus 로고
    • Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma
    • Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M (2013) Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest 123(12): 5104-5118.
    • (2013) J Clin Invest , vol.123 , Issue.12 , pp. 5104-5118
    • Marsh Durban, V.1    Deuker, M.M.2    Bosenberg, M.W.3    Phillips, W.4    McMahon, M.5
  • 58
    • 84896451505 scopus 로고    scopus 로고
    • Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma
    • Menzies AM, Haydu LE, Carlino MS, Azer MW, Carr PJ, Kefford RF, Long GV (2014) Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS ONE 9(1): e85004.
    • (2014) PLoS ONE , vol.9 , Issue.1 , pp. e85004
    • Menzies, A.M.1    Haydu, L.E.2    Carlino, M.S.3    Azer, M.W.4    Carr, P.J.5    Kefford, R.F.6    Long, G.V.7
  • 67
    • 84888639050 scopus 로고    scopus 로고
    • K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
    • Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM (2013) K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503(7477): 548-551.
    • (2013) Nature , vol.503 , Issue.7477 , pp. 548-551
    • Ostrem, J.M.1    Peters, U.2    Sos, M.L.3    Wells, J.A.4    Shokat, K.M.5
  • 77
    • 84883016265 scopus 로고    scopus 로고
    • BRAF in melanoma: Current strategies and future directions
    • Salama AK, Flaherty KT (2013) BRAF in melanoma: current strategies and future directions. Clin Cancer Res 19(16): 4326-4334.
    • (2013) Clin Cancer Res , vol.19 , Issue.16 , pp. 4326-4334
    • Salama, A.K.1    Flaherty, K.T.2
  • 80
    • 33745075558 scopus 로고    scopus 로고
    • Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases
    • Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5(5):1136-1144.
    • (2006) Mol Cancer Ther , vol.5 , Issue.5 , pp. 1136-1144
    • Smalley, K.S.1    Haass, N.K.2    Brafford, P.A.3    Lioni, M.4    Flaherty, K.T.5    Herlyn, M.6
  • 81
    • 79951961755 scopus 로고    scopus 로고
    • Resistance to BRAF inhibition in melanomas
    • Solit DB, Rosen N (2011) Resistance to BRAF inhibition in melanomas. New Engl J Med 364(8): 772-774.
    • (2011) New Engl J Med , vol.364 , Issue.8 , pp. 772-774
    • Solit, D.B.1    Rosen, N.2
  • 84
    • 1442274619 scopus 로고    scopus 로고
    • Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma
    • Tsao H, Goel V, Wu H, Yang G, Haluska FG (2004) Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 122(2): 337-341.
    • (2004) J Invest Dermatol , vol.122 , Issue.2 , pp. 337-341
    • Tsao, H.1    Goel, V.2    Wu, H.3    Yang, G.4    Haluska, F.G.5
  • 87
    • 84907986134 scopus 로고    scopus 로고
    • Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma
    • e-pub ahead of print 24 June 2014
    • Vu HL, Aplin AE (2014) Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma. Mol Cancer Res; e-pub ahead of print 24 June 2014.
    • (2014) Mol Cancer Res
    • Vu, H.L.1    Aplin, A.E.2
  • 93
    • 84873911646 scopus 로고    scopus 로고
    • Activity of the heat shock protein 90 inhibitor ganetespib in melanoma
    • Wu X, Marmarelis ME, Hodi FS (2013) Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS ONE 8(2): e56134.
    • (2013) PLoS ONE , vol.8 , Issue.2 , pp. e56134
    • Wu, X.1    Marmarelis, M.E.2    Hodi, F.S.3
  • 94
    • 84904152952 scopus 로고    scopus 로고
    • A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: A road map for the study of genes with potential clinical relevance
    • Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W, Zhao Z (2014) A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. Mol Cancer Ther 13(7): 1918-1928.
    • (2014) Mol Cancer Ther , vol.13 , Issue.7 , pp. 1918-1928
    • Xia, J.1    Jia, P.2    Hutchinson, K.E.3    Dahlman, K.B.4    Johnson, D.5    Sosman, J.6    Pao, W.7    Zhao, Z.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.